2024-10-16 - Analysis Report
## AbbVie Inc (ABBV) Stock Analysis:

**Company Overview:** AbbVie Inc. is a global pharmaceutical company focused on developing and commercializing innovative therapies for various diseases.

**1. Performance Comparison:**

* **Cumulative Return:** ABBV has outperformed the S&P 500 (VOO) with a cumulative return of 152.4% compared to 135.82%. 
* **Relative Outperformance:**  ABBV is currently outperforming the S&P 500 by 16.58%. This represents a relative outperformance of 58.07% based on the historical range of outperformance.

**2. Recent Price Movement:**

* **Closing Price:** $194.19
* **5-Day Moving Average:** $193.87
* **20-Day Moving Average:** $194.26
* **60-Day Moving Average:** $191.73
* **Analysis:** The stock is trading slightly above its 5-day and 20-day moving averages, suggesting potential for continued upward momentum. The price is also above the 60-day moving average, indicating a longer-term bullish trend.

**3. Technical Indicators:**

* **RSI:** 51.02 -  Indicates the stock is neither overbought nor oversold.
* **PPO:** -0.14 - Suggests a possible slowdown in momentum, though not necessarily a bearish signal.
* **Delta_Previous_Relative_Divergence:** -6.63 - Indicates a recent decline in relative outperformance, potentially signaling a temporary dip in the stock's performance.
* **Expected Return:** 1.6587% -  Represents a 5-year estimated potential for exceeding S&P 500 returns.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS | 
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

* **Analysis:** AbbVie consistently exceeded earnings estimates in the past few quarters. This positive trend suggests strong underlying business performance and future potential.

**5. News and Recent Issues:**

* **Recent Market Outlook for ABBV:** The market expects continued strong performance from AbbVie, driven by the success of its key drugs like Humira, Rinvoq, and Skyrizi. 
* **Analyst Opinions and Performance Highlights:** 
    * Many analysts have a "Buy" or "Strong Buy" rating on ABBV, citing its strong earnings, robust pipeline, and potential for continued growth.
    * FINBOLD highlights AbbVie as a potential investment opportunity, emphasizing its growth potential, dividend yield, and long-term outlook.

**6. Overall Analysis:**

ABBV exhibits a strong track record of outperforming the market with consistent earnings and a robust pipeline. The current technical indicators suggest some potential for a temporary dip in momentum. However, the long-term outlook remains positive, supported by analyst opinions and the company's strong performance.

**7. Conclusion:**

Overall, AbbVie (ABBV) presents a compelling investment opportunity for investors seeking a long-term growth stock with a solid track record. The company's strong earnings, pipeline, and analyst sentiment support its future potential. However, investors should monitor the stock's short-term trends and potential for near-term volatility. 
